Gefticip Tablet contains Gefitinib 250mg, an oral tyrosine kinase inhibitor used primarily in the treatment of non-small cell lung cancer (NSCLC). Gefitinib selectively inhibits the epidermal growth factor receptor (EGFR) tyrosine kinase, which is involved in the signaling pathways that regulate cell proliferation and survival. By blocking EGFR activity, Gefitinib impedes tumor growth and induces apoptosis in cancer cells expressing EGFR mutations. Gefticip is indicated for patients with locally advanced or metastatic NSCLC harboring specific EGFR mutations, particularly exon 19 deletions or exon 21 (L858R) substitution mutations. The medication is administered once daily, with or without food, and requires careful patient selection based on molecular diagnostic testing to ensure efficacy. Common adverse effects include diarrhea, rash, acneiform dermatitis, and elevated liver enzymes, necessitating regular monitoring of hepatic function and clinical status. Caution is advised in patients with pre-existing interstitial lung disease or hepatic impairment. Gefticip should be used under oncological supervision, with periodic assessment of tumor response and toxicity. Dose adjustments or discontinuation may be required in cases of severe adverse reactions. This targeted therapy represents a significant advancement in personalized cancer treatment, improving progression-free survival in EGFR-mutated NSCLC patients.